CRISPR-edited hepatic organoids as drug screening platform for non-alcoholic fatty liver disease  

作　　者：Yinhan Wang Haifeng Xu 

机构地区：[1]Department of Liver Surgery,Peking Union Medical College(PUMC)Hospital,Peking Union Medical College(PUMC)&Chinese Academy of Medical Sciences(CAMS),Beijing,China

出　　处：《Hepatobiliary Surgery and Nutrition》2023年第4期593-594,共2页肝胆外科与营养(英文)

基　　金：supported by the National High Level Hospital Clinical Research Funding(No.2022-PUMCH-B-034).

摘　　要：Non-alcoholic fatty liver disease(NAFLD),is a chronic liver disease caused by a build-up of intrahepatic fat.Metabolic comorbidities associated with NAFLD included obesity,type 2 diabetes,hyperlipidemia,hypertension,and metabolic syndrome(1-3).With changes in diet and lifestyle,the incidence of NAFLD is rapidly increasing to an estimated 30%of global population(4).Histologic manifestations of NAFLD range from the mild stage of simple steatosis,to the advanced stage of steatosis accompanied with necroinflammation or fibrosis,so called nonalcoholic non-alcoholic steatohepatitis(NASH).

关 键 词：CRISPR ORGANOIDS non-alcoholic fatty liver disease(NAFLD) drug screening 

分 类 号：R575.5[医药卫生—消化系统]